You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma

Version: 4 ID: 8-1 Dec 2017
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
Members of the Melanoma Disease Site Group

Patient Population

Adult patients with high-risk malignant melanoma who are rendered disease-free following resection. Patients who would now be classified as American Joint Committee on Cancer (AJCC) stage IIB, IIC and III. For this practice guideline, high risk is defined as patients in the following clinical states:

  1. Primary melanoma with tumour thickness 4.0 mm
  2. Primary melanoma with in-transit metastases
  3. Positive sentinel lymph nodes
  4. Primary melanoma with regional lymph node metastases that are clinically apparent
  5. Regional lymph node recurrence
  6. Involved nodes were excised but there was no known primary melanoma

Intended Guideline Users

Clinicians and healthcare providers involved in the management and referral of patients with resected melanoma at high risk for recurrence.

Research Question(s)

What systemic therapy should clinicians recommend to patients who have been rendered diseasefree following the resection of cutaneous melanomas and who are at high risk for subsequent recurrence?

pdf download Summary (PDF) (572.9 KB)